New drug trial aims to wipe out Early-Stage lymphoma
NCT ID NCT06796998
Summary
This study is testing an investigational drug called epcoritamab in adults who have just been diagnosed with marginal zone lymphoma (MZL) and have not yet received any treatment. The main goal is to see how many participants achieve a complete response, meaning no detectable cancer can be found on scans after 12 cycles of therapy. Researchers will closely monitor how well the drug works and its side effects over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.